SoylentNews

takyon [soylentnews.org] writes:

The BBC reports on a small trial (12 patients) that used psilocybin to treat "moderate-to-severe, unipolar, treatment-resistant" depression [bbc.com]:

A hallucinogenic chemical in magic mushrooms shows promise for people with untreatable depression, a short study on just 12 people hints. Eight patients were no longer depressed after the "mystical and spiritual" experience induced by the drug. The findings, in the Lancet Psychiatry [thelancet.com] [open, DOI: 10.1016/S2215-0366(16)30065-7], showed five of the patients were still depression-free after three months.

Experts cautiously welcomed the findings as "promising, but not completely compelling". There have now been calls for the drug to be tested in larger trials.

From the study:

Psilocybin's acute psychedelic effects typically became detectable 30–60 min after dosing, peaked 2–3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0–1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference −11·8, 95% CI −9·15 to −14·35, p=0·002, Hedges' g=3·1) and 3 months (−9·2, 95% CI −5·69 to −12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.

Original Submission